Archon Biosciences is at the forefront of biotechnology, focusing on the development of a novel class of biologics known as Antibody Cages (AbCs). These biologics are engineered through advanced computational design techniques that allow for precise control over their structural properties, including size, shape, and binding characteristics. By integrating the proven binding affinity and specificity of traditional antibodies with innovative generative protein design, AbCs can target complex biological pathways that have previously been difficult to engage. This unique approach enables Archon to create therapeutics with differentiated distribution and enhanced functionality, addressing significant challenges in drug development.

The AbC platform leverages artificial intelligence and computational protein design, recognized by the 2024 Nobel Prize in Chemistry, to produce a diverse library of geometrically tunable protein therapeutics. This technology allows for the rapid assembly of antibodies into defined nanostructures, which can be tailored for specific therapeutic applications. Archon’s methodology not only retains the established efficacy of antibodies but also enhances their therapeutic potential by enabling better control over biodistribution and target engagement. This innovative approach positions Archon Biosciences to revolutionize the treatment landscape for diseases that have been historically challenging to address.

United States

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.

We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Archon Biosciences

Company Details